TPG Biotech

growth-positive

Asset manager TPG has increased its Life Science Innovations fund to a total of $580 million. The fund is used to support emerging life science companies, with a focus on those working in various medical fields and on different drug modalities and technology platforms. TPG will use this round of fundraising to seek companies across the spectrum, from preclinical to commercial to medical devices and pharma services. The $580 million in capital includes commitments from TPG’s The Rise Fund, which was used to contribute to Sionna Therapeutics’ $182 million series C in March.